OPTICROM
Clinical safety rating: caution
Comprehensive clinical and safety monograph for OPTICROM (OPTICROM).
Mast cell stabilizer; inhibits release of histamine and other inflammatory mediators from mast cells.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine and bile. |
| Excretion | Primarily excreted unchanged in urine (approximately 50-60%) and feces (approximately 40-50%) via biliary elimination. |
| Half-life | Terminal elimination half-life is approximately 80-100 minutes in adults; clinically, this supports dosing every 4-6 hours for sustained effect. |
| Protein binding | Approximately 65% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 0.2-0.3 L/kg; low Vd indicates limited extravascular distribution, consistent with poor tissue penetration except at sites of administration. |
| Bioavailability | Oral bioavailability is <1% due to poor absorption; ophthalmic and inhalation routes provide local delivery with minimal systemic absorption. |
| Onset of Action | Ophthalmic administration: onset within minutes for relief of ocular itching; inhalation: onset within 2-4 weeks for prophylactic effect in asthma. |
| Duration of Action | Ophthalmic: duration of effect is 4-6 hours; inhalation: duration of prophylactic effect persists for several hours after single dose, requires regular dosing for sustained benefit. |
2 drops in each eye 4 times daily. Administration: ophthalmic topical.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Children ≥4 years: 1-2 drops in each eye 4 times daily. For children <4 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use same as adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for OPTICROM (OPTICROM).
| Breastfeeding | Excretion in human milk unknown; M/P ratio not available. Due to low systemic absorption, exposure to infant is expected to be minimal. Use with caution. |
| Teratogenic Risk | No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. Risk cannot be excluded. Inhaled cromolyn sodium has minimal systemic absorption, likely low risk throughout pregnancy. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to cromolyn sodium or any component of the formulation.
| Precautions | Contains benzalkonium chloride; may be absorbed by soft contact lenses. Discontinue if ocular symptoms worsen. Use with caution in patients with hepatic or renal impairment. |
Loading safety data…
| No specific monitoring required; standard prenatal care. Monitor for any adverse reactions in mother. |
| Fertility Effects | No known adverse effects on fertility in animal studies; no human data. |